Aclarion Inc Revenue Growth Rates (ACON), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Aclarion Inc   (NASDAQ: ACON)
    Sector • Healthcare    Industry • Medical Laboratories
   Industry • Medical Laboratories
   Sector • Healthcare
 

ACON's Revenue Growth by Quarter and Year

Aclarion Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/ACON/growth
https://api.csimarket.com/api/v1/companies/ACON/fundamentals
https://api.csimarket.com/api/v1/companies/ACON/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API
Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery
Connect Your AI Assistant
How to Connect Your AI Assistant to CSIMarket MCP MCP Server
Access this full dataset via API
Free sample Full docs All endpoints
ACON Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 0.03
2nd Quarter June 0.03
1st Quarter March 0.02
FY 0.08





ACON Revenue third quarter 2026 Y/Y Growth Comment
Aclarion Inc achieved in the third quarter 2026, above Company average Revenue rise of 68.66% year on year, to $ 0.03 millions.

Looking into third quarter 2026 results within Medical Laboratories industry 14 other companies have achieved higher Revenue growth. While Aclarion Inc ' s Revenue jump of 68.66% ranks overall at the positon no. 1096 in the third quarter 2026.


ACON Revenue ( Y/Y Growth %) 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 68.66 %
2nd Quarter June 50 %
1st Quarter March 0 %
FY   -

Financial Statements
Aclarion Inc 's third quarter 2026 Revenue $ 0.03 millions ACON's Income Statement
Aclarion Inc 's third quarter 2025 Revenue $ 0.02 millions Quarterly ACON's Income Statement


ACON Revenue (Quarter on Quarter Growth %)

 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 12.44 %
2nd Quarter June 50 %
1st Quarter March 0 %
FY (Year on Year)   -


Back to ACON Growth rate Comparisons >> Back to ACON Growth rate Comparisons >>


Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry #15
Healthcare Sector #207
Overall #1096

Revenue Y/Y Growth Statistics
High Average Low
95.49 % 18.04 % -41.41 %
(Jun 30 2023)   (Sep 30 2024)
Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry #15
Healthcare Sector #207
Overall #1096
Revenue Y/Y Growth Statistics
High Average Low
95.49 % 18.04 % -41.41 %
(Jun 30 2023)   (Sep 30 2024)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Aclarion Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
116.95 % 10.58 % -57.42 %
(Jun 30 2021)  


ACON's III. Quarter Q/Q Revenue Comment
In the III. Quarter 2026 Aclarion Inc disclosed increase in Revenue from the second quarter by 12.44% to $ 0.03 millions, from $ 0.03 millions achived in the previous reporting period.

Within Medical Laboratories industry only one company achieved higher sequential Revenue growth. While Aclarion Inc 's Revenue growth quarter on quarter, overall rank is 243.


Revenue Q/Q Growth Company Ranking
Within: No.
Medical Laboratories Industry #2
Healthcare Sector #66
Overall #243
Revenue Q/Q Growth Company Ranking
Within: No.
Medical Laboratories Industry #2
Healthcare Sector #66
Overall #243
Revenue Q/Q Growth Statistics
High Average Low
116.95 % 10.58 % -57.42 %
(Jun 30 2021)  


ACON's III. Quarter Q/Q Revenue Comment
In the III. Quarter 2026 Aclarion Inc disclosed increase in Revenue from the second quarter by 12.44% to $ 0.03 millions, from $ 0.03 millions achived in the previous reporting period.

Within Medical Laboratories industry only one company achieved higher sequential Revenue growth. While Aclarion Inc 's Revenue growth quarter on quarter, overall rank is 243.


Aclarion Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)		 12 Months Ending (Mar 31 2026) 12 Months Ending (Dec 31 2025) 12 Months Ending (Sep 30 2025) 12 Months Ending (Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 0.08
Y / Y Revenue Growth (TTM) 33.07 %
Year on Year Revenue Growth Overall Ranking # 1027
Seqeuential Revenue Change (TTM) 7.56 %
Seq. Revenue Growth (TTM) Overall Ranking # 1096


Cumulative Revenue growth Comment
Assuming the Aclarion Inc 's fiscal year would have ended in Jun 30 2026, Aclarion Inc would have reprted above average annual Revenue rise of 33.07% year on year, of $ 0 millions.
This marks a slow-down of the companys growth trends and from the 42.63% increase in Mar 31 2026.

In the Healthcare sector 194 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 1027, from total ranking in previous quarter at 2602.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry # 15
Healthcare Sector # 195
Overall # 1027

Revenue TTM Y/Y Growth Statistics
High Average Low
95.49 %
 18.04 %
-41.41 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 15
Sector # 207
S&P 500 # 1096
Cumulative Revenue growth Comment
Assuming the Aclarion Inc 's fiscal year would have ended in Jun 30 2026, Aclarion Inc would have reprted above average annual Revenue rise of 33.07% year on year, of $ 0 millions.
This marks a slow-down of the companys growth trends and from the 42.63% increase in Mar 31 2026.

In the Healthcare sector 194 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 1027, from total ranking in previous quarter at 2602.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry # 15
Healthcare Sector # 195
Overall # 1027

Revenue TTM Y/Y Growth Statistics
High Average Low
95.49 %
18.04 %
-41.41 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 15
Sector # 207
S&P 500 # 1096




Other Revenue Growth
Medical Laboratories Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
ACON's Revenue Growth Ratio versus Medical Laboratories Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue increase for the quarter ending Sep 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2026
Sonida Senior Living Inc 114.40%$ 114.402 millions
Verastem Inc 113.59%$ 113.592 millions
Hyperfine Inc 109.27%$ 109.270 millions
Pelthos Therapeutics Inc 107.87%$ 107.872 millions
Co diagnostics Inc 94.58%$ 94.580 millions
Autolus Therapeutics Plc94.57%$ 94.574 millions
Qt Imaging Holdings Inc exact Name Of Registrant As Specified In Its Charter _______________________93.02%$ 93.022 millions
Keros Therapeutics Inc 88.77%$ 88.766 millions
Profound Medical Corp 85.86%$ 85.857 millions
Vivosim Labs Inc 82.14%$ 82.143 millions
Syndax Pharmaceuticals Inc 81.59%$ 81.592 millions
Iovance Biotherapeutics inc 80.07%$ 80.074 millions
Rhythm Pharmaceuticals Inc 79.59%$ 79.594 millions
Omniab Inc 78.34%$ 78.339 millions
Aclarion Inc 78.09%$ 78.086 millions
Personalis Inc 76.59%$ 76.585 millions
Delcath Systems Inc 76.05%$ 76.047 millions
Mobia Medical Inc 73.28%$ 73.280 millions
Wave Life Sciences Ltd 72.95%$ 72.950 millions
Igc Pharma Inc 71.73%$ 71.728 millions
Phathom Pharmaceuticals Inc 71.14%$ 71.142 millions
Ptc Therapeutics inc 69.57%$ 69.571 millions
Seres Therapeutics Inc 68.95%$ 68.946 millions
Alamar Biosciences Inc 68.46%$ 68.458 millions
Carlsmed Inc 66.74%$ 66.736 millions
Corcept Therapeutics Inc63.97%$ 63.974 millions
Tarsus Pharmaceuticals Inc 63.92%$ 63.921 millions
Tg Therapeutics Inc 60.74%$ 60.743 millions
Heartflow Inc 60.42%$ 60.425 millions
Glaukos Corp59.02%$ 59.021 millions


About Aclarion Inc Revenue Growth Rates (ACON), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Aclarion Inc (CIK 1635077).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001683168-26-008355
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Aclarion Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.